Adamantanes
Two drugs that share the adamantane cage and almost nothing else. Memantine is a low-affinity, uncompetitive NMDA receptor antagonist and a prescription medicine for moderate-to-severe Alzheimer's disease, so it is the one molecule in this subject with a regulator's label behind it. Bromantane was developed in Russia, where it is registered as a medicine under the name Ladasten and described as an "actoprotector", a Soviet-era category with no Western equivalent. Its mechanism is reported as raising dopamine synthesis rather than releasing it.
Neither should be read as harmless because one is prescribed. Memantine's NMDA antagonism is the same mechanism as the dissociatives', and it adds to theirs and to DXM's. Bromantane has been on the World Anti-Doping Agency's prohibited list since positive tests at the 1996 Olympics. Bought as a powder, neither comes with the assay that a pharmacy product carries.
No posts here yet.